Coya Therapeutics, a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), announced that it has appointed Dieter Weinand to its board of directors, effective immediately. Coya will leverage Weinand’s extensive experience, connections, and judgement to guide Coya’s strategic discussions and development programs.

“I am delighted to join the board of Coya, a company whose science has the potential to make a significant clinical difference in patients’ lives suffering from difficult to treat neurodegenerative diseases, an experienced leadership team that I believe can unlock the full potential of the therapies, and a cohesive board of directors. I look forward to becoming a part of this remarkable company,” Mr. Weinand commented.

“Coya has strengthened its DNA with Dieter. Having his counsel, guidance, and network available to Coya at this time will bolster our profile in 'big picture’ opportunities including business development and strategic discussions. His selection to join Coya at this point in his career is a validating moment for us,” stated Howard Berman, Ph.D, CEO of Coya.

Dieter Weinand is an experienced executive with over 25 years of experience in the pharmaceuticals and biotech industries. Weinand presently serves as the Chairman of the Board of Directors of Replimune Group Inc., Mnemo Therapeutics, Umoja Biopharma, Inc., Inspirna, Inc., and Ziel Bio, Inc.

Previously, he was the Chief Executive Officer and Chairman of the Board of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Bayer, Weinand held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka.